Onconova (NASDAQ: ONTX) was devalued by Zacks  from a “acquire” ranking to a “hold” rating in a research note issued to capitalists on Thursday, Zacks.com reports.

According to Zacks, “Onconova Therapeutics, Inc. operates as a clinical-stage biopharmaceutical business. It concentrates on finding as well as developing tiny molecule medicine candidates to deal with cancer cells. The Company‘s products under various phases of development consist of Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 as well as Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania. “

Several other equities research analysts also just recently talked about the company. Noble Financial reissued a “purchase” score and provided a $11.00 rate goal on shares of Onconova Therapeutics in a report on Thursday, September 23rd. Guggenheim dropped their rate target on Onconova Therapeutics from $29.00 to $12.00 and also set a “get” score on the stock in a research note on Tuesday, September 28th.

NASDAQ: ONTX opened up at $2.25 on Thursday. Onconova Therapeutics has a twelve month low of $2.22 and a twelve month high of $28.95. Business has a 50 day relocating typical cost of $2.90 and a two-hundred day relocating ordinary price of $4.16. The firm has a market cap of $46.76 million, a P/E ratio of -1.82 as well as a beta of 1.67.

Onconova Therapeutics (NASDAQ: ONTX) last launched its quarterly earnings outcomes on Thursday, November 11th. The biopharmaceutical business reported ($ 0.22) revenues per share for the quarter, topping analysts’ consensus estimates of ($ 0.33) by $0.11. Onconova Therapeutics had an adverse return on equity of 59.78% and an unfavorable web margin of 8,294.27%. The firm had revenue of $0.06 million throughout the quarter, contrasted to the consensus price quote of $0.06 million. During the very same quarter in the previous year, the firm published ($ 0.45) EPS. En masse, research experts forecast that Onconova Therapeutics will certainly upload -1.18 EPS for the current year.

A variety of hedge funds have recently dealt shares of ONTX. GSA Funding Allies LLP bought a brand-new position in Onconova Therapeutics during the 3rd quarter worth $922,000. Hudson Bay Funding Administration LP purchased a brand-new setting in shares of Onconova Therapeutics in the 3rd quarter worth $635,000. Pura Vida Investments LLC bought a new position in shares of Onconova Therapeutics in the 3rd quarter worth $575,000. CVI Holdings LLC purchased a new position in shares of Onconova Therapeutics in the third quarter worth $493,000. Ultimately, Dimensional Fund Advisors LP bought a brand-new position in shares of Onconova Therapeutics in the 2nd quarter worth $509,000. Hedge funds as well as other institutional financiers have 13.36% of the business’s stock.

Concerning Onconova Therapeutics

Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical firm, which engages in the recognition as well as development of oncology therapeutics. It focuses on discovering and creating little particle medication prospects to deal with cancer. The firm was founded by Ramesh Kumar and E. Premkumar Reddy on December 22, 1998 and also is headquartered in Newtown, PA

. Obtain a totally free duplicate of the Zacks research report on Onconova Therapeutics (ONTX).

To find out more regarding research offerings from Zacks Investment Research, go to Zacks.com.

This instant information alert was produced by narrative science innovation and also monetary data from Market in order to offer visitors with the fastest as well as most precise coverage. This tale was reviewed by Market’s content group prior to magazine. 

 

SHOULD YOU SPEND $1,000 IN ONCONOVA THERAPEUTICS NOW?

Before you take into consideration Onconova Therapeutics, you’ll wish to hear this.

Market keeps an eye on Wall Street’s top-rated as well as best executing research experts as well as the stocks they recommend to their clients on a daily basis. Market has determined the 5 stocks that cover experts are silently whispering to their customers to buy now prior to the broader market catches on … as well as Onconova Therapeutics had not been on the list.

While Onconova Therapeutics currently has a “Buy” score among analysts, top-rated analysts believe these 5 stocks are much better purchases.